Sarepta Therapeutics, Inc. (NASDAQ: SRPT) announces its next round of earnings this Wednesday, Oct. 24. Here's
Benzinga's advanced look at Sarepta's Q3 earnings report.
Earnings and Revenue
Sarepta's per-share loss will be near 82 cents on sales of $79.21 million, according to Wall Street analysts.
Sarepta reported a loss of 20 cents when it published results during the same quarter last year. Sales in that period totaled
$45.95 million. If the company were to report inline earnings when it publishes results Wednesday, earnings would be up
310 percent. Revenue would be up 72.37 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up
against analyst estimates in the past:
| Quarter |
Q2 2018 |
Q1 2018 |
Q4 2017 |
Q3 2017 |
| EPS Estimate |
-0.84 |
-0.32 |
-0.32 |
-0.86 |
| EPS Actual |
-0.43 |
-0.28 |
-0.28 |
-0.2 |
Stock Performance
Over the last 52-week period, shares are up 158.61 percent. Given that these returns are generally positive, long-term
shareholders should be satisfied going into this earnings release.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts generally rate Sarepta stock
as Neutral. The strength of this rating has maintained conviction over the past three months.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.